• Explore /
  • Poster
  • / Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Abstract Poster

Authors

null

Yoshihiko Tomita

Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Yoshihiko Tomita , Robert J. Motzer , Toni K. Choueiri , Brian I. Rini , Hideaki Miyake , Hirotsugu Uemura , Laurence Albiges , Yosuke Fujii , Yoshiko Umeyama , Jing Wang , Mariangela Mariani , Manuela Schmidinger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02684006

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 301)

DOI

10.1200/JCO.2021.39.6_suppl.301

Abstract #

301

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Sun Young Rha

First Author: Nizar M. Tannir

First Author: John B. A. G. Haanen

First Author: Yoshihiko Tomita